Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fluocinonide
Drug ID BADD_D00925
Description A topical glucocorticoid used in the treatment of eczema.
Indications and Usage A topical anti-inflammatory product for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Marketing Status Prescription; Discontinued
ATC Code C05AA11; D07AC08
DrugBank ID DB01047
KEGG ID D00325
MeSH ID D005447
PubChem ID 9642
TTD Drug ID D03ZZK
NDC Product Code 63629-2508; 0093-0262; 70771-1393; 62991-2865; 68682-992; 45802-151; 68462-505; 43386-026; 70771-1375; 71085-004; 70710-1284; 72578-087; 68071-4619; 53002-9201; 0093-0264; 51552-0056; 68071-2202; 63629-2337; 68071-2200; 16714-502; 50090-1671; 71428-001; 0168-0134; 47781-569; 43386-095; 53002-9200; 0093-0263; 47781-602; 68788-8105; 50090-2419; 50090-3277; 71085-005; 70700-146; 63629-2339; 46439-8707; 68071-4921; 63629-2510; 51672-1254; 68071-2541; 66267-973; 69238-1534; 0713-0664; 68071-1654; 52128-176; 68788-7541; 68071-4732; 68071-2667; 49452-3161; 40032-026; 59088-755; 52565-025; 40032-095; 0713-0803; 50090-1784; 68788-7706; 51672-1386; 51672-1253; 51672-1264; 33342-320; 71205-092; 52565-079; 50090-2982; 51672-1279; 68071-1754; 0168-0135; 51672-1353; 52565-040; 51672-1273; 63629-2509; 53002-9202; 63187-033; 71085-006; 69238-1271; 52565-054; 51862-494; 0472-0829; 68071-4219; 99207-525; 0168-0457; 63629-2338
Synonyms Fluocinonide | Fluocinolone Acetonide 21-Acetate | Acetonide 21-Acetate, Fluocinolone | Fluocinolone Acetonide 21 Acetate | Fluocinonide FAPG | FAPG, Fluocinonide | Fluocinolide | Lidex | Lidemol | Lyderm | Tiamol | Topsyne | Novoter | Topsym | Topsyn | Klariderm | Metosyn
Chemical Information
Molecular Formula C26H32F2O7
CAS Registry Number 356-12-7
SMILES CC(=O)OCC(=O)C12C(CC3C1(CC(C4(C3CC(C5=CC(=O)C=CC54C)F)F)O)C)OC(O2)(C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acne23.02.01.001--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Application site reaction12.07.01.006; 08.02.01.006--Not Available
Atrophy08.03.04.001--Not Available
Cataract subcapsular06.06.01.002--Not Available
Condition aggravated08.01.03.004--Not Available
Cushing's syndrome24.08.04.001; 19.07.03.002; 14.11.01.007; 05.01.01.001--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis acneiform23.02.01.004--
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry skin23.03.03.001--
Erythema23.03.06.001--Not Available
Folliculitis23.09.04.007; 11.01.12.018--
Glycosuria20.02.01.005--
Headache17.14.01.001--
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hypersensitivity10.01.03.003--
Hypertrichosis23.02.04.002--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Leukoderma23.05.02.001--Not Available
Miliaria23.02.03.014--Not Available
Nasal congestion22.04.04.001--
Nasopharyngitis11.01.13.002; 22.07.03.002--Not Available
Nervous system disorder17.02.10.001--Not Available
Pain08.01.08.004--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Secondary adrenocortical insufficiency14.11.01.014; 05.01.02.003--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages